The privatization of the Chinese stockholder Aikang Guobin has been full of twists and turns.
First, I met the healthy privatization offer of the US, and then the chairman and CEO Zhang Ligang released the "poison pill plan", followed by the second price increase in the US, to raise the price of the second year of the defense, Zhang Ligang upgraded the buyer group and introduced Alibaba. Waiting for investors, and launching a series of lawsuits against the United States.
Recently, this deadlocked confrontation situation has been broken - the Yunfeng Fund jointly initiated by Ma Yun and Yan Feng initiated a privatization offer for Aikang Guobin:
On June 6, the Yunfeng Fund jointly initiated by Ma Yun and Yan Feng initiated a privatization offer to Aikang Guobin;
On June 7, Zhang Ligang announced his withdrawal from the founding consortium to the special committee of Elken.
On June 8th, the US Announcement of Health and Welfare announced that it would no longer submit a binding offer to the Special Committee of the Ikang Guobin and decided to withdraw from the buyer group.
So far, this privatization equity battle that has lasted for half a year has come to an end.
This result, perhaps Yu Rong, chairman of the US Health Association, has predicted that in an exclusive interview with China Entrepreneur magazine earlier this year, he said that in addition to capital, there is a sense of urgency to promote him to fight this battle. Because BAT also has channels to enter the health field: “A lot of things can happen in three years. If you don’t integrate now, you will miss a best golden opportunity. After three years, this is not necessarily the turn of us. It is."
It is a pity that the two sides with the idea of ​​industry integration have not been able to talk about it.
After announcing the withdrawal from the buyer's group, the US-year-old said to the magazine: "Our participation in the privatization bidding of Aikang is intended to promote the industry to develop in a more benign direction, rather than simply pursuing a larger scale and market share, if Yunfeng joins It will make the overall ecological environment of the health checkup industry more active and healthy. We believe that the need to continue such bidding acquisition has been greatly reduced. Considering the current market environment, the costs and impacts in the relevant process need to be re-examined."
In an open letter issued this morning, Zhang Ligang said that he is willing to withdraw due to personal development and business management considerations, and cooperates with well-known and friendly investors in the acquisition of Elken:
In the past six months, I have been fighting against a hostile takeover offer from a competitive consortium including Ikon's competitors. To a certain extent, this struggle has distracted my attention to the internal management of the company. If friendly investors can bring value to Aikang's long-term development through alliances or mergers and acquisitions, I will fully cooperate. For the company's long-term interests, if my full exit from the Aikang shareholder level and management level will help well-known and friendly investors to buy Aikang, I am willing to leave when the acquisition is completed.
As the founder of Aikang, this is a very difficult decision for Zhang Ligang. According to reports from relevant media, people familiar with the two sides said that Yunfeng Fund is not the white knight who Zhang Ligang invited.
In contrast, Ikang Guobin’s share price movement in Nasdaq in the past month has seen a cliff-like decline from May 5 to 12, and the stock price has dropped from 21.45 yuan to 17.23 yuan, a drop of nearly 20%. Then it rose steadily and rose back to 21.12 yuan on June 6, but it was 5% lower on the 7th.
The focus turned to Yunfeng Fund, and its paper suggested that the privatization of the Ikang Guobin changed dramatically. It is worth mentioning that at the beginning of this year, Zhang Ligang had an Alibaba in the buyer group, but the buyer group did not raise the quotation for privatization. In addition, according to the regulations, the parties to the new consortium still have the right to withdraw at any time.
[Sample requirements]
The collected nasopharyngeal swab samples should be transported at 2°C to 8°C and sent for inspection immediately, and the sample delivery and storage time should not exceed 48 hours.
[Testing method]
1. Before sampling, mark the relevant sample information on the label of the sampling tube.
2. According to different sampling requirements, use a sampling swab to sample in the nasopharynx.
3. The specific sampling methods are as follows:
a) Nasal swab: Gently insert the swab head into the nasal palate, stay for a while and then slowly turn to exit. Wipe the other nostril with another swab, immerse the swab head in the sampling solution, and discard the tail.
b) Pharyngeal swab: Wipe bilateral pharyngeal tonsils and posterior pharyngeal wall with a swab, also immerse the swab head in the sampling solution, and discard the tail.
4. Quickly put the swab into the sampling tube.
5. Break the part of the sampling swab higher than the sampling tube, and tighten the tube cover.
6. Freshly collected clinical specimens should be transported to the laboratory within 48 hours at 2°C to 8°C.
[Explanation of test results]
After the sample is collected, the sampling solution turns slightly yellow, which will not affect the nucleic acid test result.
[Limitations of the test method]
1. For samples that are seriously contaminated due to improper storage after collection, the final test results will be affected.
2. If the sample is not stored at the specified temperature, the final test result will be affected.
Vtm Sampling Tube With Swab,Disposable Collection Tube Of Virus Samples,Hi Media Vtm Kit,Amylase Sample Collection Tube
Jilin Sinoscience Technology Co. LTD , https://www.jilinsinoscience.com